Symbols / TRAW
TRAW Chart
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.23M |
| Enterprise Value | 5.81M | Income | -9.16M | Sales | 2.85M |
| Book/sh | 0.64 | Cash/sh | 0.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -0.35 | PEG | — |
| P/S | 4.30 | P/B | 2.40 | P/C | — |
| EV/EBITDA | -0.37 | EV/Sales | 2.04 | Quick Ratio | 1.07 |
| Current Ratio | 1.22 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.82 | EPS next Y | -4.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 07:00 | ROA | -92.29% |
| ROE | -10.60% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.55% | Profit Margin | 0.00% | Shs Outstand | 7.99M |
| Shs Float | 3.80M | Short Float | 11.32% | Short Ratio | 1.44 |
| Short Interest | — | 52W High | 4.50 | 52W Low | 0.97 |
| Beta | 1.67 | Avg Volume | 318.15K | Volume | 74.06K |
| Target Price | $7.25 | Recom | Strong_buy | Prev Close | $1.43 |
| Price | $1.53 | Change | 6.99% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$1.53
Latest analyst target
3. DCF / Fair value
$-26.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.53
Low
$6.50
High
$8.00
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-03 | init | HC Wainwright & Co. | — → Buy | $8 |
- COVID pill in trial shows fewer side effects than Paxlovid, eyes monthly flu use - Stock Titan hu, 19 Feb 2026 12
- TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits Mon, 26 Jan 2026 08
- Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com hu, 19 Feb 2026 15
- Traws Pharma Stock Plunges As FDA Halts TXM IND - RTTNews hu, 19 Feb 2026 14
- Aug Action: Is TRAW a cyclical or defensive stock - 2025 Momentum Check & Accurate Trade Setup Notifications - baoquankhu1.vn Wed, 25 Feb 2026 02
- Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data - TipRanks hu, 19 Feb 2026 14
- TRAW - Traws Pharma Latest Stock News & Market Updates - Stock Titan Mon, 26 Jan 2026 08
- HC Wainwright & Co. Initiates Coverage of Traws Pharma (TRAW) with Buy Recommendation - Nasdaq Wed, 03 Dec 2025 08
- 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga hu, 19 Feb 2026 17
- Traws Pharma Reports Promising Interim Data for Ratutrelvir, Showing Favorable Profile Compared to PAXLOVIDâ„¢ in COVID-19 Treatment | TRAW Stock News - Quiver Quantitative Wed, 17 Dec 2025 08
- New COVID pill shows fewer side effects than Paxlovid in early test - Stock Titan Wed, 17 Dec 2025 08
- COVID pill shows faster recovery, fewer side effects than Paxlovid - Stock Titan ue, 13 Jan 2026 08
- Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives - Stock Titan Mon, 06 Oct 2025 07
- COVID drug tested in Paxlovid-ineligible patients as monthly flu pill advances - Stock Titan Mon, 26 Jan 2026 08
- Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com Mon, 26 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4058 | — | — | Stock Award(Grant) at price 0.00 per share. | LEAMAN JOHN HAROLD | Director | — | 2025-12-12 00:00:00 | D |
| 1 | 36943 | — | — | Stock Award(Grant) at price 0.00 per share. | DUKES IAIN D | Chief Executive Officer | — | 2025-12-12 00:00:00 | D |
| 2 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | SHOEMAKER MARY TERESA | Director | — | 2025-12-12 00:00:00 | D |
| 3 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | CLARKE TRAFFORD PH.D. | Director | — | 2025-12-12 00:00:00 | D |
| 4 | 18471 | — | — | Stock Award(Grant) at price 0.00 per share. | PAUZA CHARLES DAVID | Officer | — | 2025-12-12 00:00:00 | D |
| 5 | 4874 | — | — | Stock Award(Grant) at price 0.00 per share. | CAUTREELS WERNER C | Director | — | 2025-12-12 00:00:00 | D |
| 6 | 16419 | — | — | Stock Award(Grant) at price 0.00 per share. | REDFIELD ROBERT | Officer | — | 2025-12-12 00:00:00 | D |
| 7 | 16419 | — | — | Stock Award(Grant) at price 0.00 per share. | SAVCHUK NIKOLAY | Chief Operating Officer | — | 2025-12-12 00:00:00 | D |
| 8 | 6157 | — | — | Stock Award(Grant) at price 0.00 per share. | STOVER JACK E | Director | — | 2025-12-12 00:00:00 | D |
| 9 | 96348 | 963.0 | — | Conversion of Exercise of derivative security at price 0.01 per share. | CAUTREELS WERNER C | Chief Executive Officer | — | 2025-02-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 117.00M | -20.28M | -19.61M | -16.80M |
| TotalUnusualItems | -141.90M | 0.00 | 321.00K | |
| TotalUnusualItemsExcludingGoodwill | -141.90M | 0.00 | 321.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -166.52M | -18.95M | -18.96M | -16.16M |
| ReconciledDepreciation | 12.00K | 16.00K | 14.00K | 14.00K |
| EBITDA | -24.90M | -20.28M | -19.61M | -16.48M |
| EBIT | -24.91M | -20.30M | -19.63M | -16.50M |
| NormalizedIncome | -24.62M | -18.95M | -18.96M | -16.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -166.52M | -18.95M | -18.96M | -16.16M |
| TotalExpenses | 25.14M | 20.52M | 19.85M | 16.72M |
| TotalOperatingIncomeAsReported | -142.37M | -20.30M | -19.63M | -16.50M |
| DilutedAverageShares | 1.55M | 839.55K | 836.33K | 673.29K |
| BasicAverageShares | 1.55M | 839.55K | 836.33K | 673.29K |
| DilutedEPS | -35.21 | -22.57 | -22.75 | -24.00 |
| BasicEPS | -35.21 | -22.57 | -22.75 | -24.00 |
| DilutedNIAvailtoComStockholders | -54.67M | -18.95M | -18.96M | -16.16M |
| NetIncomeCommonStockholders | -54.67M | -18.95M | -18.96M | -16.16M |
| PreferredStockDividends | -111.85M | |||
| NetIncome | -166.52M | -18.95M | -18.96M | -16.16M |
| NetIncomeIncludingNoncontrollingInterests | -166.52M | -18.95M | -18.96M | -16.16M |
| NetIncomeContinuousOperations | -166.52M | -18.95M | -18.96M | -16.16M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -166.52M | -18.95M | -18.96M | -16.16M |
| OtherIncomeExpense | -141.61M | 1.35M | 663.00K | 333.00K |
| OtherNonOperatingIncomeExpenses | 289.00K | 1.35M | 663.00K | 12.00K |
| SpecialIncomeCharges | -117.46M | 0.00 | ||
| OtherSpecialCharges | 117.46M | |||
| GainOnSaleOfSecurity | -24.44M | 321.00K | ||
| OperatingIncome | -24.91M | -20.30M | -19.63M | -16.50M |
| OperatingExpense | 25.14M | 20.52M | 19.85M | 16.72M |
| ResearchAndDevelopment | 12.85M | 11.43M | 11.41M | 7.30M |
| SellingGeneralAndAdministration | 12.29M | 9.09M | 8.45M | 9.43M |
| GeneralAndAdministrativeExpense | 12.29M | 9.09M | 8.45M | 9.43M |
| OtherGandA | 7.18M | 4.13M | 3.21M | 4.34M |
| InsuranceAndClaims | 860.00K | 985.00K | 1.29M | 1.42M |
| SalariesAndWages | 4.24M | 3.98M | 3.95M | 3.67M |
| TotalRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| OperatingRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 3.65M | 840.14K | 837.04K | 835.82K |
| ShareIssued | 3.65M | 840.14K | 837.04K | 835.82K |
| TangibleBookValue | -31.63M | 10.67M | 28.31M | 46.12M |
| InvestedCapital | -31.63M | 10.67M | 28.31M | 46.12M |
| WorkingCapital | 13.42M | 13.44M | 31.30M | 49.31M |
| NetTangibleAssets | -31.63M | 10.67M | 28.31M | 46.12M |
| CommonStockEquity | -31.63M | 10.67M | 28.31M | 46.12M |
| TotalCapitalization | -31.63M | 10.67M | 28.31M | 46.12M |
| TotalEquityGrossMinorityInterest | -31.63M | 10.67M | 28.31M | 46.12M |
| StockholdersEquity | -31.63M | 10.67M | 28.31M | 46.12M |
| GainsLossesNotAffectingRetainedEarnings | -42.00K | -23.00K | -33.00K | -14.00K |
| OtherEquityAdjustments | -42.00K | -23.00K | -33.00K | -14.00K |
| RetainedEarnings | -649.15M | -482.63M | -463.68M | -444.72M |
| AdditionalPaidInCapital | 617.53M | 493.32M | 491.82M | 490.64M |
| CapitalStock | 36.00K | 9.00K | 209.00K | 209.00K |
| CommonStock | 36.00K | 9.00K | 209.00K | 209.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 56.59M | 12.01M | 11.06M | 9.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 45.06M | 2.79M | 3.02M | 3.24M |
| DerivativeProductLiabilities | 42.49M | 0.00 | 0.00 | |
| NonCurrentDeferredLiabilities | 2.56M | 2.79M | 3.02M | 3.24M |
| NonCurrentDeferredRevenue | 2.56M | 2.79M | 3.02M | 3.24M |
| CurrentLiabilities | 11.53M | 9.22M | 8.05M | 6.12M |
| CurrentDeferredLiabilities | 226.00K | 226.00K | 226.00K | 226.00K |
| CurrentDeferredRevenue | 226.00K | 226.00K | 226.00K | 226.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 265.00K | 1.00M | 1.19M | 1.22M |
| PayablesAndAccruedExpenses | 11.04M | 7.99M | 6.63M | 4.67M |
| CurrentAccruedExpenses | 2.86M | 2.37M | 2.77M | 1.92M |
| Payables | 8.19M | 5.62M | 3.86M | 2.76M |
| AccountsPayable | 8.19M | 5.62M | 3.86M | 2.76M |
| TotalAssets | 24.96M | 22.68M | 39.37M | 55.48M |
| TotalNonCurrentAssets | 11.00K | 23.00K | 25.00K | 48.00K |
| OtherNonCurrentAssets | 1.00K | 1.00K | 1.00K | 10.00K |
| NetPPE | 10.00K | 22.00K | 24.00K | 38.00K |
| AccumulatedDepreciation | -74.00K | -62.00K | -46.00K | -32.00K |
| GrossPPE | 84.00K | 84.00K | 70.00K | 70.00K |
| MachineryFurnitureEquipment | 84.00K | 84.00K | 70.00K | 70.00K |
| CurrentAssets | 24.95M | 22.66M | 39.35M | 55.43M |
| OtherCurrentAssets | 178.00K | 401.00K | 40.00K | 35.00K |
| PrepaidAssets | 1.67M | 1.42M | 521.00K | 297.00K |
| Receivables | 1.76M | 18.00K | 29.00K | 28.00K |
| AccountsReceivable | 1.76M | 18.00K | 29.00K | 28.00K |
| CashCashEquivalentsAndShortTermInvestments | 21.34M | 20.82M | 38.76M | 55.07M |
| CashAndCashEquivalents | 21.34M | 20.82M | 38.76M | 55.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.79M | -17.95M | -16.29M | -19.49M |
| IssuanceOfCapitalStock | 33.98M | 0.00 | 0.00 | 55.04M |
| CapitalExpenditure | -14.00K | |||
| EndCashPosition | 21.34M | 20.82M | 38.76M | 55.07M |
| BeginningCashPosition | 20.82M | 38.76M | 55.07M | 19.02M |
| EffectOfExchangeRateChanges | -19.00K | 10.00K | -19.00K | -28.00K |
| ChangesInCash | 536.00K | -17.95M | -16.29M | 36.07M |
| FinancingCashFlow | 33.98M | 0.00 | 0.00 | 55.56M |
| CashFlowFromContinuingFinancingActivities | 33.98M | 0.00 | 0.00 | 55.56M |
| ProceedsFromStockOptionExercised | 0.00 | 519.00K | ||
| NetCommonStockIssuance | 33.98M | 0.00 | 0.00 | 55.04M |
| CommonStockIssuance | 33.98M | 0.00 | 0.00 | 55.04M |
| InvestingCashFlow | -3.65M | -14.00K | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -3.65M | -14.00K | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -3.65M | 0.00 | ||
| PurchaseOfBusiness | -3.65M | 0.00 | ||
| NetPPEPurchaseAndSale | 0.00 | -14.00K | 0.00 | 0.00 |
| PurchaseOfPPE | 0.00 | -14.00K | 0.00 | 0.00 |
| OperatingCashFlow | -29.79M | -17.93M | -16.29M | -19.49M |
| CashFlowFromContinuingOperatingActivities | -29.79M | -17.93M | -16.29M | -19.49M |
| ChangeInWorkingCapital | -6.57M | -301.00K | 1.48M | -3.59M |
| ChangeInOtherWorkingCapital | -226.00K | -226.00K | -226.00K | -226.00K |
| ChangeInOtherCurrentAssets | 0.00 | 9.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -4.57M | 1.17M | 1.93M | -3.91M |
| ChangeInAccruedExpense | -5.22M | -585.00K | 828.00K | -1.83M |
| ChangeInPayable | 646.00K | 1.76M | 1.10M | -2.08M |
| ChangeInAccountPayable | 646.00K | 1.76M | 1.10M | -2.08M |
| ChangeInPrepaidAssets | -27.00K | -1.26M | -229.00K | 530.00K |
| ChangeInReceivables | -1.75M | 11.00K | -1.00K | 9.00K |
| OtherNonCashItems | 117.46M | |||
| StockBasedCompensation | 1.39M | 1.30M | 1.17M | 576.00K |
| DepreciationAmortizationDepletion | 12.00K | 16.00K | 14.00K | 14.00K |
| DepreciationAndAmortization | 12.00K | 16.00K | 14.00K | 14.00K |
| OperatingGainsLosses | 24.44M | -321.00K | ||
| GainLossOnInvestmentSecurities | 24.44M | -321.00K | ||
| NetIncomeFromContinuingOperations | -166.52M | -18.95M | -18.96M | -16.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TRAW
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|